Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: Report from the get with the guidelines coronary artery disease program

Clinical Cardiology

Volumn 35, Issue 9, 2012, Pages 541-547

  Vasaiwala, Samip ^a   Cannon, Christopher P ^a,c   Fonarow, Gregg C ^d   Peacock, W Frank ^e   Laskey, Warren ^f   Schwamm, Lee H ^g   Liang, Li ^h   Hernandez, Adrian F ^h   Peterson, Eric D ^h   Rosas, Sylvia E ^b,i   Bhatt, Deepak L ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEALTH PROGRAM; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE;

AGED; CORONARY ARTERY DISEASE; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84866256731     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22021     Document Type: Article

References (18)

1. Kidney Disease Outcomes Quality Initiative Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003; 41 (4 suppl 3):I-IV, S1-S91.
2. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003; 63: 1121-1129.
3. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003; 41: 47-55.
4. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134: 629-636.
5. Herzog CA, Ma JZ, Collins AJ., Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998; 339: 799-805.
6. Mishkel GJ, Varghese JJ, Moore AL, et al. Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. J Invasive Cardiol. 2007; 19: 331-337.
7. Papafaklis MI, Naka KK, Papamichael ND, et al. The impact of renal function on the long-term clinical course of patients who underwent percutaneous coronary intervention. Catheter Cardiovasc Interv. 2007; 69: 189-197.
8. Mueller C, Neumann FJ, Perruchoud AP, et al. Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. Heart. 2004; 90: 902-907.
9. Gruberg L, Dangas G, Mehran R, et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv. 2002; 55: 66-72.
10. Blackman D, Pinto R, Ross J, et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J. 2006; 151: 146-152.
11. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes. JAMA. 2004; 292: 2096-2104.
12. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162: 1401-1408.
13. Berger AK, Duval S, Krumholz HM., Aspirin, β-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003; 42: 201-208.
14. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010; 121: 357-365.
15. Stenvinkel P, Alvestrand A., Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002; 15: 329-337.
16. Himmelfarb J., Chronic kidney disease and the public health. JAMA. 2007; 297: 2630-2633.
17. Coca SG, Krumholz HM, Garg AX, et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006; 296: 1377-1384.
18. LaBresh KA, Ellrodt AG, Gliklich R, et al. Get With the Guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004; 164: 203-209.